CHIR-98014
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


CHIR-98014
Description:
CHIR-98014 is a potent, cell-permeable GSK-3 inhibitor with IC50s of 0.65 and 0.58 nM for GSK-3α and GSK-3β, respectively; it shows less potent activities against cdc2 and erk2.UNSPSC:
12352005Hazard Statement:
H302, H315, H319, H335Target:
GSK-3Type:
Reference compoundRelated Pathways:
PI3K/Akt/mTOR; Stem Cell/WntApplications:
Metabolism-sugar/lipid metabolismField of Research:
Metabolic DiseaseAssay Protocol:
https://www.medchemexpress.com/CHIR-98014.htmlPurity:
98.44Solubility:
DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)Smiles:
ClC1=CC(Cl)=CC=C1C2=NC(NCCNC3=CC=C([N+]([O-])=O)C(N)=N3)=NC=C2N4C=CN=C4Molecular Formula:
C20H17Cl2N9O2Molecular Weight:
486.31Precautions:
H302, H315, H319, H335References & Citations:
[1]Ring DB, et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52 (3) :588-95.|[2]Naujok O, et al. Cytotoxicity and activation of the Wnt/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors. BMC Res Notes. 2014 Apr 29;7:273.|[3]Zajkowski T, et al. Stabilization of microtubular cytoskeleton protects neurons from toxicity of N-terminal fragment of cytosolic prion protein. Biochim Biophys Acta. 2015 Oct;1853 (10 Pt A) :2228-39.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Reference compound1Clinical Information:
No Development ReportedIsoform:
GSK-3α; GSK-3βCAS Number:
252935-94-7
